Myasthenia gravis surgery

Jump to navigation Jump to search

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis surgery

CDC on Myasthenia gravis surgery

Myasthenia gravis surgery in the news

Blogs on Myasthenia gravis surgery

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The mainstay of surgical treatment of MG is thymectomy. Thymectomy means removing as much thymic tissue as possible. This treatment is done for patients with thymoma and even in patients without thymoma and who have generalized MG with AChR antibodies.

Indications

Surgery

References

  1. Romi F (2011). "Thymoma in myasthenia gravis: from diagnosis to treatment". Autoimmune Dis. 2011: 474512. doi:10.4061/2011/474512. PMC 3155972. PMID 21860784.
  2. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW (July 2010). "Guidelines for treatment of autoimmune neuromuscular transmission disorders". Eur. J. Neurol. 17 (7): 893–902. doi:10.1111/j.1468-1331.2010.03019.x. PMID 20402760.
  3. Jani-Acsadi A, Lisak RP (May 2010). "Myasthenia gravis". Curr Treat Options Neurol. 12 (3): 231–43. doi:10.1007/s11940-010-0070-0. PMID 20842584.
  4. Kumar V, Kaminski HJ (February 2011). "Treatment of myasthenia gravis". Curr Neurol Neurosci Rep. 11 (1): 89–96. doi:10.1007/s11910-010-0151-1. PMID 20927659.
  5. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (July 2016). "International consensus guidance for management of myasthenia gravis: Executive summary". Neurology. 87 (4): 419–25. doi:10.1212/WNL.0000000000002790. PMC 4977114. PMID 27358333.
  6. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A, Newsom-Davis J, Cutter GR (August 2016). "Randomized Trial of Thymectomy in Myasthenia Gravis". N. Engl. J. Med. 375 (6): 511–22. doi:10.1056/NEJMoa1602489. PMC 5189669. PMID 27509100.
  7. Sonett JR, Jaretzki A (2008). "Thymectomy for nonthymomatous myasthenia gravis: a critical analysis". Ann. N. Y. Acad. Sci. 1132: 315–28. doi:10.1196/annals.1405.004. PMID 18567883.

Template:WH Template:WS